Collegium Pharmaceutical (COLL) Cash & Equivalents (2014 - 2026)

Collegium Pharmaceutical has reported Cash & Equivalents for 13 years, with the latest figure at $129.5 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 10.33% year-over-year to $129.5 million in Q2 2026; TTM through Jun 2026 was $129.5 million, a 10.33% increase from a year earlier, with the FY2025 full-year figure at $231.3 million, up 227.71% from the prior year.
• Cash & Equivalents was $129.5 million for Q2 2026 at Collegium Pharmaceutical, down from $268.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $283.7 million in Q2 2023, with the low at $39.0 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $171.8 million, with a median of $161.5 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 84.93% in 2024, then soared 285.26% in 2025.
• Over 5 years, Cash & Equivalents stood at $173.7 million in 2022, then soared by 37.57% to $238.9 million in 2023, then plunged by 70.47% to $70.6 million in 2024, then soared by 227.71% to $231.3 million in 2025, then slumped by 44.01% to $129.5 million in 2026.
• The last three Cash & Equivalents figures came in at $129.5 million (Q2 2026), $268.6 million (Q1 2026), and $231.3 million (Q4 2025), per Business Quant data.